Pfizer’s Premarin for Menopause Linked to Blood Clot Risk
This article is for subscribers only.
Pfizer’s Inc.’s Premarin for menopause may be tied to a higher risk of blood clots than another common estrogen treatment called estradiol, a study found.
Women taking Premarin, also known as conjugated equine estrogens, had double the risk of a blood clot in the veins than women taking estradiol, a synthetic form of estrogen, according to research today in JAMA Internal Medicine. No difference between the treatments was seen in the risk of stroke.